Healthcare / Medical Instruments & SuppliesShenzhen
$8.45
+0.04 (+0.48%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-412.9M · quality 45.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.0B
P/E
15.9x
↓EV/EBITDA
8.1x
↓ROE
4.6%
↑Gross Margin
32.2%
↓Debt/Equity
0.26
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-3.7%
FCF CAGR
—
FCF margin
8.5%
FCF / Net income
1.92x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.76B · net income $254.7M · FCF $489.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.76B | $5.76B | $5.83B | $6.85B | $6.45B |
| Net Income | $254.7M | $254.7M | $-452.7M | $317.1M | $567.4M |
| EBITDA | $612.5M | $612.5M | $-245.7M | $585.5M | $802.4M |
| EPS | 0.43 | 0.43 | -0.77 | 0.55 | 0.97 |
| Gross Margin | 32.2% | 32.2% | 25.9% | 31.5% | 36.0% |
| Operating Margin | 7.1% | 7.1% | -3.1% | 6.2% | 10.0% |
| Net Margin | 4.4% | 4.4% | -7.8% | 4.6% | 8.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.26 | 0.26 | 0.53 | 0.15 | 0.12 |
| Current Ratio | 1.27 | 1.27 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $489.5M | $489.5M | $-581.2M | $-412.9M | $-810.3M |
| Returns | |||||
| ROE | 4.6% | 4.6% | -10.6% | 6.7% | 13.5% |
| Valuation | |||||
| P/E | 15.94 | 15.94 | — | 18.98 | 15.48 |
| EV/EBITDA | 8.09 | 8.09 | — | 10.21 | 10.18 |
| P/B | 0.91 | 0.91 | 0.90 | 1.28 | 2.08 |
| Growth & Yield | |||||
| Revenue Growth | -1.1% | -1.1% | -14.9% | 6.3% | — |
| EPS Growth | 155.6% | 155.6% | -240.5% | -43.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
20.7%
EPS terminal req.
$0.75
Spread vs growth
134.9%
5Y implied EPS CAGR
16.3%
EPS terminal req.
$0.91
Spread vs growth
139.3%
10Y implied EPS CAGR
13.1%
EPS terminal req.
$1.46
Spread vs growth
142.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+11.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.77 → 0.43
Residual
+11.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.